

1 **Increased Severity of New-onset Type 1 Diabetes in Children and Adolescents during the** 2 **COVID-19 Pandemic: Experience from a Tertiary Care Center in Serbia**

3 **Damjan Jovanovic¹, Jelena Blagojevic², Dejana Stanisavljevic^{1,3}, Maja Jesic^{1,2}**

4 ¹Faculty of Medicine, University of Belgrade, Serbia

5 ²Department of Pediatric Endocrinology, University Children's Hospital, Belgrade, Serbia

6 ³ Department of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Serbia

7 **Abstract:** *Background and objectives:* Public health measures, parental fear of infection, and redeployment of
8 medical resources in response to the COVID-19 pandemic might have led to a decrease in pediatric healthcare access.
9 As a result, a delay in type 1 diabetes diagnosis might have occurred, leading to the worsening of its clinical
10 presentation in the pediatric population. This study aimed to examine the clinical and biochemical features of new-
11 onset DM1 in children and adolescents during the COVID-19 pandemic, comparing it to the pre-pandemic period.
12 *Materials and methods:* The clinical and biochemical features of diabetes observed during the COVID-19 period from
13 April 1, 2020, until December 31, 2022, were compared with the period from April 1, 2017, until December 31, 2019.
14 In the COVID-19 pandemic group, the clinical and biochemical features were compared between children with and
15 without SARS-CoV-2 infection at diagnosis or before the diagnosis of DM1. *Results:* During the COVID-19 pandemic,
16 observed frequencies of DKA and severe DKA at diagnosis were 47.6% and 20.7%, both significantly higher than
17 during the pre-pandemic period (an absolute increase of 15% and 11.3%, respectively). In the COVID-19 group, blood
18 pH levels were significantly lower than in the pre-pandemic group, while HbA1c levels were higher. Clinical and
19 biochemical features of diabetes in children with SARS-CoV-2 infection at or before the diagnosis were not
20 significantly different compared to children without an infection. *Conclusion:* We report a significant worsening of
21 the clinical presentation of new-onset type 1 diabetes and an increase in the frequency of DKA and severe DKA at
22 diagnosis during the COVID-19 pandemic. Further studies are necessary to gain quantitative insight into pediatric
23 healthcare availability in Serbia.

24 **Keywords:** COVID-19; pandemic; Type 1 diabetes; diabetic ketoacidosis; children and adolescents; Serbia

25 **1. Introduction**

26 COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
27 CoV-2). The first cases of SARS-CoV-2 infection were reported in December 2019 in Wuhan, China. [1] The
28 first laboratory-confirmed case of SARS-CoV-2 infection in Serbia was reported on March 6, 2020 [2], and
29 the World Health Organization (WHO) declared COVID-19 a pandemic on March 11 of the same year. [1]
30 The COVID-19 pandemic has proven itself to be a great challenge for healthcare systems and societies as
31 a whole throughout the world. In the Republic of Serbia, as in many other countries, a series of public
32 health measures were introduced to curb the viral spread throughout the population. In response to a
33 rising number of patients with a moderate to severe clinical presentation of the SARS-CoV-2 infection, a
34 substantial number of hospitals were adapted for the treatment and care of COVID-19. Additionally,
35 numerous healthcare professionals were redeployed from their regular units to specialized COVID-19
36 centers. While severe forms of the disease in children are uncommon, it's essential to recognize that poor
37 outcomes are still plausible within the pediatric population. [3,4] Furthermore, children often act as
38 asymptomatic carriers of the virus and may serve as a significant link in the transmission chain of the
39 disease. [5,6] For those reasons, children were also subjected to public health measures.

40 Public health measures, parental fear of infection, and redeployment of healthcare system resources may
41 have led to a decrease in pediatric healthcare availability and resulted in a delay in the diagnosis and
42 treatment of other diseases [7–9], such as type 1 diabetes. A survey of the perception and experience of
43 healthcare professionals from pediatric centers carried out during the first year of the pandemic showed
44 that a significant number of respondents reported a delay in the diagnosis of diabetes and an increase in
45 DKA frequency. [10] Indeed, a number of groups reported an increase in DKA and severe DKA prevalence
46 on the initial presentation of newly diagnosed type 1 diabetes in children and adolescents during the
47 pandemic. [11–15] Healthcare system overload and a decrease in pediatric healthcare access and
48 utilization may have led to a delay in DM 1 diagnosis and a worsening of the clinical picture and

49 biochemical parameters of the disease in the Republic of Serbia as well. To evaluate this hypothesis, we
50 collected the data on disease characteristics (blood glucose levels, HbA1c, pH, DKA frequency and
51 severity) of newly diagnosed DM 1 cases presenting to the University Children’s Hospital, Belgrade, Serbia,
52 over the 33 months of the COVID-19 pandemic and compared them with the data for the 33-month period
53 that immediately preceded the pandemic. Besides the indirect effects of the pandemic on the clinical
54 picture of DM 1, there is a possibility of a direct effect of the SARS-CoV-2 infection on the biology of the
55 disease. To evaluate the mechanistic effect of infection on the severity of metabolic disorder in DM 1, we
56 compared clinical and biochemical features of the disease between children who had the SARS-CoV-2
57 infection at or before the diagnosis of DM 1 and children who didn’t.

58 **2. Materials and Methods**

59 The study was designed as a single-center, retrospective observational study. The study population
60 included children and adolescents less than 18 years old presenting to the Department of Pediatric
61 Endocrinology at the University Children’s Hospital (Belgrade, Serbia) with new-onset type 1 diabetes. The
62 COVID-19 pandemic group included children and adolescents admitted to our department with a new
63 diagnosis of DM 1 from April 1, 2020, to December 31, 2022, while the control group was comprised of
64 patients newly diagnosed with type 1 diabetes in the period from April 1, 2017, to December 31, 2019.
65 During the COVID-19 pandemic, every child was tested for SARS-COV-2 upon admission to the hospital
66 using a rapid antigen test (RAT), and positive results were verified using polymerase chain reaction (PCR).
67 DM1 was defined according to the criteria of the International Society for Pediatric and Adolescent
68 Diabetes (ISPAD). [16] Patients admitted with previous type 1 diabetes, non-DM1, or unclear types of
69 diabetes were excluded from the study. Data collected from paper and electronic medical charts included
70 sex, age, residence, date of DM 1 diagnosis, as well as the clinical features of the disease (symptom
71 duration, blood pH, blood glucose levels, and DKA/severe DKA on presentation). Diabetic ketoacidosis

72 (DKA) was defined as the presence of: (1) blood glucose > 11 mmol/l, (2) blood pH < 7.3 or bicarbonate <
73 15 mmol/l, and (3) ketonemia or ketonuria. Severe DKA was defined as pH < 7.1. [17] In the pandemic
74 group, data were collected on the presence of SARS-CoV-2 infection before the DM1 diagnosis (history of
75 a positive PCR, positive RAT in the presence of symptoms, or presence of SARS-CoV-2 IgM/IgG antibodies
76 at any point before the diagnosis of type 1 diabetes) or at the initial presentation of DM1 (results of RAT
77 upon admission to the hospital).

78 **2.1. Statistical analysis**

79 Data are presented as means \pm standard deviation for continuous variables with a normal distribution or
80 as numbers (percentages) for nominal variables. For comparisons between the pandemic group and pre-
81 pandemic control group, as well as between the children with and without SARS-CoV-2 infection before
82 or at the diagnosis of DM1 in the pandemic group, t-test and ANOVA were conducted for continuous
83 variables, and the Chi-square test for nominal variables. A two-sided $P < 0.05$ was considered statistically
84 significant. The data were analyzed using the Statistical Package for the Social Sciences (SPSS) Version 21
85 software.

86 **3. Results**

87 A total of 143 children and adolescents presented with a new-onset DM1 over the 33-month study period
88 during the COVID-19 pandemic, in comparison to 135 patients presenting during the equally lasting
89 control period preceding the pandemic. The demographic characteristics of the pandemic and control
90 groups did not differ significantly (Table 1). The average number of new DM1 cases per month during the
91 pandemic and control period was 4.33 and 4.09, respectively. The highest average number of cases per
92 month was recorded in 2021 (5.33), while the lowest was observed in 2018 (3.00) (Figure S1A).

Table 1. Demographic and clinical/biochemical characteristics of new onset DM1 during the COVID-19 pandemic period (April 1, 2020 to December 31, 2022) and the pre-pandemic control group (April 1, 2017 to December 31, 2019) and the pandemic group

Characteristic		Pandemic group	Control group	P value
Number of new DM1 cases	Total	143	135	/
Age	Mean ± standard deviation	9.98 ± 4.46	9.58 ± 4.39	0.446
Sex	Male	66 (46.2 %)	75 (55.6 %)	0.117
	Female	77 (53.8 %)	60 (44.4 %)	
Residence	City of Belgrade	82 (57.3 %)	88 (65.2 %)	0.18
	Other	61 (42.7 %)	47 (34.8 %)	
Duration of symptoms	Inconclusive	7	2	0.002
	≤ 7 days	54 (39.7 %)	28 (21.1 %)	
	8 – 30 days	65 (47.8 %)	76 (57.1 %)	
	≥ 30 days	17 (12.5 %)	29 (21.8 %)	
pH	Mean ± standard deviation	7.245 ± 0.175	7.317 ± 0.139	<0.001
Blood glucose level (mmol/l)	Mean ± standard deviation	23.573 ± 9.123	22.824 ± 8.767	0.487
HbA1c (%)	Mean ± standard deviation	11.041 ± 2.052	10.613 ± 1.389	0.045
DKA (%)	Total	47.6	32.6	0.011
Severe DKA (%)	Total	20.7	9.4	0.010

93

94 Mean blood pH values were significantly lower in the pandemic group compared to the control group

95 (7.245 ± 0.175 during the pandemic vs. 7.317 ± 0.139 during the control period, P < 0.001) (Figure 1B),

96 while the HbA1c levels were significantly higher (11.041 ± 2.052 vs. 10.613 ± 1.389, P = 0.045) (Figure 1C).

97 Mean blood glucose values were higher in the pandemic group, albeit non-significantly. The percentage


98 of children presenting within 7 days of the onset of symptoms was higher during the pandemic (39.7% vs.

99 21.1%, P = 0.002), while the percentage of children with the duration of symptoms > 30 days was lower

100 (12.5% vs. 21.8%) (Table 1). During the COVID-19 pandemic, the frequency of DKA at the initial

101 presentation of type 1 diabetes was strikingly increased as compared to the control period (47.6% during

102 the pandemic vs. 32.6% during the control period ($P = 0.011$), an absolute increase of 15%). The presence
103 of severe DKA at the onset of DM1 was also significantly more common in the pandemic group (20.7% vs.
104 9.4%, $P = 0.01$), with an absolute increase of 11.3%. (Table 1 and Figure 1A)



105




Figure 2. Clinical and biochemical characteristics of new onset DM1 during the COVID-19 pandemic period (April 1, 2020 to December 31, 2022) and the pre-pandemic control group (April 1, 2017 to December 31, 2019) and the pandemic group. A. During the COVID-19 pandemic frequencies of DKA and severe DKA at diagnosis were 47.6% and 20.7%, both significantly higher than during the pre-pandemic period (an absolute increase of 15% and 11.3%, respectively). **B, C.** HbA1c levels were significantly higher in the pandemic group, while blood pH levels were higher.

110 pandemic group, higher blood glucose levels were noticed in younger patients (27.096 ± 7.322 in children
111 aged < 5 years, 23.832 ± 9.402 in children aged 5–11 years, and 21.928 ± 9.243 in children aged ≥ 11 years,

112 P = 0.049). Such a trend of age-related decrease in mean blood glucose level wasn't seen in the control
 113 group (Table 2 and Figure S2). The duration of symptoms in the pre-pandemic period was significantly
 114 shorter among children aged < 5 years in comparison to other age categories (Table 2). There were no
 115 significant differences in the duration of symptoms between the age groups during the COVID-19
 116 pandemic. In the control group, the frequency of DKA was the highest in children aged < 5 years. While
 117 the observed difference did not reach statistical significance, it's worth noting that the p-value (0.056)
 118 was borderline, and its significance would have likely been revealed in a larger sample. (Table 2)

Table 2. Age-specific distribution of clinical and biochemical characteristics in individuals newly diagnosed with DM1 during the COVID-19 pandemic and the control period

Characteristic		Pandemic group			Control group			P value	
		< 5 years	5 – 10 years	≥ 11 years	< 5 years	5 – 10 years	≥ 11 years	Pandemic group	Control group
Age	≤ 7 days	48%	45.1%	31.7%	18.2%	23.7%	19.2%	0.139	0.025
	8 – 30 days	52%	43.1%	50%	81.8%	55.9%	48.1%		
	> 30 days	0%	11.8%	18.3%	0%	20.3%	32.7%		
	≥ 30 days								
pH	Mean ± standard deviation	7.231 ± 0.175	7.219 ± 0.192	7.271 ± 0.159	7.259 ± 0.153	7.320 ± 0.136	7.334 ± 0.133	0.263	0.130
Blood glucose level (mmol/l)	Mean ± standard deviation	27.096 ± 7.322	23.832 ± 9.402	21.928 ± 9.243	20.309 ± 9.033	24.653 ± 9.115	21.748 ± 7.959	0.049	0.076
HbA1c (%)	Mean ± standard deviation	10.969 ± 1.739	10.985 ± 1.905	11.119 ± 2.308	10.659 ± 1.003	10.593 ± 1.400	10.615 ± 1.531	0.923	0.982
DKA (%)	Total	50%	52.8%	42.2%	54.5%	28.3%	28.3%	0.498	0.056
Severe DKA (%)	Total	19.2%	27.5%	15.9%	15.8%	10.2%	6.0%	0.310	0.442

119 A total of 14 children (9.8%) from the pandemic cohort tested positive for SAR-CoV-2 upon admission (N
 120 = 6, 36.2%) or had a positive history of a laboratory-confirmed SARS-CoV-2 infection before the type 1
 121 diabetes diagnosis (N = 8, 62.8%). All children were either asymptomatic or had mild symptoms of COVID-

122 19. An additional 16 patients (11.18%) had a history of COVID-19 symptoms or a close contact (household
 123 member with a confirmed SARS-CoV-2 infection) during the pandemic. However, no definitive
 124 confirmation of the infection was established (positive PCR, positive RAT with symptoms, or the presence
 125 of SARS-CoV-2 IgM/IgG antibodies) at any point before the diagnosis of DM1. Frequencies of DKA and
 126 severe DKA at the onset of DM1 were similar between children who didn't have a SARS-CoV-2 infection
 127 before the diagnosis of DM1 and children who tested positive for SARS-CoV-2 upon admission or had a
 128 positive history of a laboratory-confirmed SARS-CoV-2 infection before the type 1 diabetes diagnosis
 129 (Table 3).

Table 3. Characteristics of new onset DM1 in children with and without SARS-CoV-2 infection before or at diagnosis of diabetes

Characteristic		No SARS-CoV-2 infection	SARS-CoV-2 infection	P value
Number of new DM1 cases	Total	129 (91.2%)	14 (9.8%)	
Age	Mean ± standard deviation	9.713 ± 4.388	12.450 ± 4.514	0.396
Sex	Male Female	63 (48.8%) 66 (51.2%)	3 (21.4%) 11 (78.6%)	0.051
Residence	City of Belgrade Other	75 (58.1%) 54 (41.9 %)	7 (50%) 7 (50%)	0.559
Duration of symptoms	≤ 7 days 8 – 30 days ≥ 30 days	39.7% 47.8% 12.5%	57.1% 28.6% 14.3%	0.295
pH	Mean ± standard deviation	7.239 ± 0.179	7.296 ± 0.130	0.254
Blood glucose level (mmol/l)	Mean ± standard deviation	23.676 ± 8.814	22.629 ± 11.964	0.685
HbA1c (%)	Mean ± standard deviation	11.128 ± 1.992	10.250 ± 2.477	0.129
DKA (%)	Total	47.3	50.0	0.847
Severe DKA (%)	Total	22.2	7.1	0.187

130

131 **4. Discussion**

132 Lower mean blood pH, higher mean HbA1c levels, and an increased prevalence of DKA/severe DKA on the
133 initial presentation of new-onset DM1 in the period from April 2020 to December 2022 in comparison to
134 the control period point to the worsening of the clinical picture of newly diagnosed type 1 diabetes among
135 children and adolescents during the pandemic in Serbia. Our results correspond to findings reported by a
136 number of groups from other countries [11–14,18–20], as well as several meta-analyses. [21,22] Multiple
137 factors have likely contributed to the substantial worsening of the clinical picture and biochemical
138 parameters of new-onset type 1 diabetes. In Serbia, as in numerous other countries, a series of public
139 health measures were introduced to suppress the transmission of SARS-CoV-2 in the population and
140 flatten the epidemic curve. As children may serve as asymptomatic carriers of the virus and less commonly
141 develop severe disease, public health interventions were implemented for the pediatric population as
142 well. Recommendations to decrease contact with other individuals were issued, the lockdown was
143 imposed several times, many people had to work from home, and schools and most other public
144 institutions were closed. Healthcare system overload led to changes in the organization of healthcare
145 services. In response to a high influx of moderate and severe cases of SARS-CoV-2 infection that required
146 hospitalization, a significant portion of healthcare professionals were redeployed from their regular units
147 to centers adapted for the treatment and care of patients with COVID-19, and scheduling specialist
148 appointments became increasingly difficult. Public health measures, parental fear of infection, healthcare
149 system overload, and a decrease in pediatric healthcare availability and utilization may have led to a delay
150 in the diagnosis and treatment of newly diagnosed DM1 in children and adolescents. Earlier investigations
151 have demonstrated that DKA is a preventable complication and that its risk is increased by a delay in DM1
152 diagnosis. [23,24] Moreover, the findings of the increased prevalences of DKA and severe DKA at the onset
153 of type 1 diabetes are particularly concerning, given that diabetic ketoacidosis is a life-threatening acute
154 complication of diabetes and commonly requires admission to the PICU unit.

155 Recent findings from several studies give evidence of an increased incidence of pediatric DM1 during the
156 COVID-19 pandemic [21,22,25,26]. Viral infections are well recognized as potential triggers for immune-
157 mediated destruction of pancreatic β cells in type 1 diabetes, and previous epidemiological research has
158 shown a rise in new cases of DM1 following viral epidemics [27]. SARS-CoV-2 was recently identified as a
159 risk factor for the development of islet autoimmunity in young children with an increased genetic risk of
160 DM1. [28] The number of newly diagnosed DM1 cases was similar between groups in this study. However,
161 even though the University Children's Hospital in Belgrade is a tertiary care center and admits the most
162 newly diagnosed type 1 cases in Serbia, it is not the only center to provide care for pediatric diabetes in
163 the country. As we don't have insight into the complete number of new type 1 diabetes cases diagnosed
164 in the territory of Serbia during the observation period, we can't estimate DM1 incidence during the
165 pandemic. Previously, an increase in the incidence of DM1 during the pandemic was reported in a multi-
166 center study in Vojvodina, which is an autonomous province of the Republic of Serbia. [29] In that study,
167 Vorgucin et al. reported that the incidence of DM1 in 2021 was the highest in a five-year period from 2017
168 to 2021. That corresponds with the finding from our study that the year 2021 had the highest average
169 number of cases per month, with the average number of cases per month decreasing to the near pre-
170 pandemic level in 2022.

171 Some authors point out the possibility of a direct relationship between SARS-CoV-2 infection and a more
172 severe clinical picture and DKA at the initial presentation of DM1. (18) SARS-CoV-2 penetrates the cells
173 after binding to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) and proteolytic cleavage
174 of the viral spike (S) protein by transmembrane serine protease 2 (TMPRSS2) [30]. ACE 2 and other viral
175 entry factors (TMPRSS2, neuropilin 1, transferrin receptor, and furin) are expressed on the surface of
176 multiple pancreatic cell types [31], and it was demonstrated that SARS-CoV-2 can infect and replicate in
177 β -cells of Langerhans islands [32–35], leading to β -cell transdifferentiation [34], suppression of insulin
178 secretion, and induction of apoptotic pathways [35]. However, the significance of the SARS-CoV-2

179 mechanistic contribution to pancreatic islet dysfunction and the severity of metabolic disturbance in DM1
180 is not yet clearly established *in vivo*. In this study, a significant difference in clinical and laboratory
181 parameters of disease severity in DM1 between children with and without SARS-CoV-2 infection before
182 or at DM1 onset was not seen. Therefore, we believe that the worsening of clinical and laboratory
183 indicators of disease severity in children was primarily caused by the indirect effects of the pandemic on
184 pediatric healthcare service organization and access. Nevertheless, the number of SARS-CoV-2-positive
185 children in our study was small, consistent with the epidemiology of SARS-CoV-2 infection in the pediatric
186 population. Additional studies are necessary to more precisely evaluate the direct relationship between
187 viral infection and the severity of new type 1 diabetes at diagnosis.

188 This study has several important limitations. The study is single-center and conducted on a relatively small
189 sample. A larger multi-center study would provide a better insight into the effects of the pandemic on
190 pediatric DM 1 in the territory of Serbia. On the other hand, several strengths compensate for these
191 limitations. The major strength of this study is its long observation period, which has covered almost the
192 entire course of the pandemic in Serbia. To our knowledge, no similar study so far has had an observation
193 period longer than 24 months. The study is also characterized by the systematic collection of data on the
194 presence of SARS-CoV-2 infection and provides an opportunity to investigate the direct effects of the viral
195 infection on the severity of DM1.

196 **5. Conclusions**

197 In conclusion, our research adds to the growing body of literature on the relationship between the severity
198 of new-onset DM1 in children and the COVID-19 pandemic. An increase in DKA and severe DKA
199 frequencies at the onset of type 1 diabetes, lower mean blood pH values, and higher mean HbA1c levels
200 confirm that the COVID-19 pandemic was associated with an increase in clinical and laboratory
201 parameters of severity of metabolic disorder in newly diagnosed cases of DM1 in the pediatric population

202 in Serbia. We believe that the worsening of the clinical picture of type 1 diabetes and the increase in
203 DKA/severe DKA at onset were caused by the interaction of multiple factors, among which healthcare
204 system overload and a decrease in pediatric healthcare access and utilization stand out as the most
205 important. Further studies are necessary to gain quantitative insight into pediatric healthcare availability
206 and access in the Republic of Serbia.

207 **Author Contributions:** Conceptualization, D.J. and M.J.; methodology, D.J., M.J., and D.S.; software, D.S.;
208 validation, D.J., M.J., and D.S.; formal analysis, D.S. and D.J.; investigation, D.J. and J.B.; resources, M.J.;
209 data curation, D.J., and J.B; writing—original draft preparation, D.J.; writing—review and editing, D.J., M.J.,
210 and D.S.; visualization, D.J. and D.S.; supervision, M.J.; project administration, M.J.; funding acquisition,
211 M.J. All authors have read and agreed to the published version of the manuscript.

212 **Funding:** This research received no external funding

213 **Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of
214 Helsinki, and approved by the Ethics Committee of the University Children’s Hospital, Belgrade (protocol
215 code 130-26/21, 2021).

216 **Informed Consent Statement:** Informed consent was obtained from all subjects or their parents or
217 guardians involved in the study for admission to hospitals and the procedures performed during
218 hospitalization. A waiver was approved for individual written informed consent to publish this paper based
219 on non-identifiable use of previously obtained retrospectively collected data.

220 **Data Availability Statement:** Data is unavailable due to privacy and ethical restrictions

221 **Acknowledgments:** The authors would like to acknowledge the children and families cared for by the
222 University Children’s Hospital.

223 **Conflicts of Interest:** The authors declare no conflict of interest.

224

225

226 **References:**

- 227 [1] WHO. World Health Organization. Timeline of WHO's response to the pandemic from 31
228 December 2019. [Internet]. 2023 [cited 2023 Jan 1]. Available from:
229 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>. n.d.
- 230 [2] Ministarstvo zdravlja Republike Srbije, Institut za javno zdravlje "Dr Milan Jovanović Batut." COVID-
231 19 [Internet]. 2023 [cited 2023 Jan 1]. Available from: <https://covid19.rs/>. n.d.
- 232 [3] Cui X, Zhao Z, Zhang T, Guo W, Guo W, Zheng J, et al. A systematic review and meta-analysis of
233 children with coronavirus disease 2019 (COVID-19). *J Med Virol* 2021;93:1057–69.
234 <https://doi.org/10.1002/jmv.26398>.
- 235 [4] Kalyanaraman M, Anderson MR. COVID-19 in Children. *Pediatr Clin North Am* 2022;69:547–71.
236 <https://doi.org/10.1016/j.pcl.2022.01.013>.
- 237 [5] Han MS, Choi EH, Chang SH, Jin B-L, Lee EJ, Kim BN, et al. Clinical Characteristics and Viral RNA
238 Detection in Children With Coronavirus Disease 2019 in the Republic of Korea. *JAMA Pediatr*
239 2021;175:73. <https://doi.org/10.1001/jamapediatrics.2020.3988>.
- 240 [6] Hippich M, Holthaus L, Assfalg R, Zapardiel-Gonzalo J, Kapfelsperger H, Heigermoser M, et al. A
241 Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than
242 Reported Cases in Children. *Med* 2021;2:149-163.e4. <https://doi.org/10.1016/j.medj.2020.10.003>.
- 243 [7] Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of
244 care in Italy resulting from fear of COVID-19. *Lancet Child Adolesc Health* 2020;4:e10–1.
245 [https://doi.org/10.1016/S2352-4642\(20\)30108-5](https://doi.org/10.1016/S2352-4642(20)30108-5).
- 246 [8] Dayal D, Gupta S, Raithatha D, Jayashree M. Missing during COVID-19 lockdown: Children with
247 onset of type 1 diabetes. *Acta Paediatr Oslo Nor* 1992 2020;109:2144–6.
248 <https://doi.org/10.1111/apa.15443>.
- 249 [9] Chanchlani N, Buchanan F, Gill PJ. Addressing the indirect effects of COVID-19 on the health of
250 children and young people. *CMAJ Can Med Assoc J J Assoc Medicale Can* 2020;192:E921–7.
251 <https://doi.org/10.1503/cmaj.201008>.
- 252 [10] Elbarbary NS, Santos TJ, Beaufort C, Agwu JC, Calliari LE, Scaramuzza AE. COVID -19 outbreak and
253 pediatric diabetes: Perceptions of health care professionals worldwide. *Pediatr Diabetes*
254 2020;21:1083–92. <https://doi.org/10.1111/pedi.13084>.
- 255 [11] Rabbone I, Schiaffini R, Cherubini V, Maffei C, Scaramuzza A, Diabetes Study Group of the Italian
256 Society for Pediatric Endocrinology and Diabetes, et al. Has COVID-19 Delayed the Diagnosis and
257 Worsened the Presentation of Type 1 Diabetes in Children? *Diabetes Care* 2020;43:2870–2.
258 <https://doi.org/10.2337/dc20-1321>.
- 259 [12] Kamrath C, Mönkemöller K, Biester T, Rohrer TR, Warncke K, Hammersen J, et al. Ketoacidosis in
260 Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic
261 in Germany. *JAMA* 2020;324:801. <https://doi.org/10.1001/jama.2020.13445>.
- 262 [13] Goldman S, Pinhas-Hamiel O, Weinberg A, Auerbach A, German A, Haim A, et al. Alarming increase
263 in ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the first
264 wave of the COVID -19 pandemic in Israel. *Pediatr Diabetes* 2022;23:10–8.
265 <https://doi.org/10.1111/pedi.13296>.

- 266 [14] Ho J, Rosolowsky E, Pacaud D, Huang C, Lemay J-A, Brockman N, et al. Diabetic ketoacidosis at type
267 1 diabetes diagnosis in children during the COVID-19 pandemic. *Pediatr Diabetes* 2021;22:552–7.
268 <https://doi.org/10.1111/pedi.13205>.
- 269 [15] Chambers MA, Mecham C, Arreola EV, Sinha M. Increase in the Number of Pediatric New-Onset
270 Diabetes and Diabetic Ketoacidosis Cases During the COVID-19 Pandemic. *Endocr Pract*
271 2022;28:479–85. <https://doi.org/10.1016/j.eprac.2022.02.005>.
- 272 [16] Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD Clinical
273 Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in
274 children and adolescents. *Pediatr Diabetes* 2018;19 Suppl 27:7–19.
275 <https://doi.org/10.1111/pedi.12773>.
- 276 [17] Wolfsdorf JL, Allgrove J, Craig ME, Edge J, Glaser N, Jain V, et al. Diabetic ketoacidosis and
277 hyperglycemic hyperosmolar state. *Pediatr Diabetes* 2014;15:154–79.
278 <https://doi.org/10.1111/pedi.12165>.
- 279 [18] Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-Onset Type 1
280 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. *Diabetes Care*
281 2020;43:e170–1. <https://doi.org/10.2337/dc20-1551>.
- 282 [19] Lawrence C, Seckold R, Smart C, King BR, Howley P, Feltrin R, et al. Increased paediatric
283 presentations of severe diabetic ketoacidosis in an Australian tertiary centre during the COVID-19
284 pandemic. *Diabet Med J Br Diabet Assoc* 2021;38:e14417. <https://doi.org/10.1111/dme.14417>.
- 285 [20] McGlacken-Byrne SM, Drew SEV, Turner K, Peters C, Amin R. The SARS-CoV-2 pandemic is
286 associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: A
287 multi-centre study of the first COVID-19 wave. *Diabet Med J Br Diabet Assoc* 2021;38:e14640.
288 <https://doi.org/10.1111/dme.14640>.
- 289 [21] Rahmati M, Keshvari M, Mirnasuri S, Yon DK, Lee SW, Il Shin J, et al. The global impact of COVID-19
290 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic
291 review and meta-analysis. *J Med Virol* 2022;94:5112–27. <https://doi.org/10.1002/jmv.27996>.
- 292 [22] D’Souza D, Empringham J, Pechlivanoglou P, Uleryk EM, Cohen E, Shulman R. Incidence of Diabetes
293 in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta-
294 Analysis. *JAMA Netw Open* 2023;6:e2321281.
295 <https://doi.org/10.1001/jamanetworkopen.2023.21281>.
- 296 [23] Sundaram PCB, Day E, Kirk JMW. Delayed diagnosis in type 1 diabetes mellitus. *Arch Dis Child*
297 2008;94:151–2. <https://doi.org/10.1136/adc.2007.133405>.
- 298 [24] Bui H, To T, Stein R, Fung K, Daneman D. Is Diabetic Ketoacidosis at Disease Onset a Result of
299 Missed Diagnosis? *J Pediatr* 2010;156:472–7. <https://doi.org/10.1016/j.jpeds.2009.10.001>.
- 300 [25] Wolf RM, Noor N, Izquierdo R, Jett D, Rewers A, Majidi S, et al. Increase in newly diagnosed type 1
301 diabetes in youth during the COVID-19 pandemic in the United States: A multi-center analysis.
302 *Pediatr Diabetes* 2022;23:433–8. <https://doi.org/10.1111/pedi.13328>.
- 303 [26] Kendall EK, Olaker VR, Kaelber DC, Xu R, Davis PB. Association of SARS-CoV-2 Infection With New-
304 Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021. *JAMA Netw Open*
305 2022;5:e2233014. <https://doi.org/10.1001/jamanetworkopen.2022.33014>.
- 306 [27] Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus — why the β cells? *Nat Rev*
307 *Endocrinol* 2016;12:263–73. <https://doi.org/10.1038/nrendo.2016.30>.
- 308 [28] Lugar M, Eugster A, Achenbach P, Von Dem Berge T, Berner R, Besser REJ, et al. SARS-CoV-2
309 Infection and Development of Islet Autoimmunity in Early Childhood. *JAMA* 2023;330:1151.
310 <https://doi.org/10.1001/jama.2023.16348>.
- 311 [29] Vorgučin I, Savin M, Stanković Đ, Miljković D, Ilić T, Simić D, et al. Incidence of Type 1 Diabetes
312 Mellitus and Characteristics of Diabetic Ketoacidosis in Children and Adolescents during the First

- 313 Two Years of the COVID-19 Pandemic in Vojvodina. *Med Kaunas Lith* 2022;58:1013.
314 <https://doi.org/10.3390/medicina58081013>.
- 315 [30] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell
316 Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*
317 2020;181:271-280.e8. <https://doi.org/10.1016/j.cell.2020.02.052>.
- 318 [31] Coate KC, Cha J, Shrestha S, Wang W, Gonçalves LM, Almacã J, et al. SARS-CoV-2 Cell Entry Factors
319 ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are
320 Not Enriched in β Cells. *Cell Metab* 2020;32:1028-1040.e4.
321 <https://doi.org/10.1016/j.cmet.2020.11.006>.
- 322 [32] Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, et al. Sars-Cov-2 Infects and
323 Replicates in Cells of the Human Endocrine and Exocrine Pancreas. *Nat Metab* 2021;3:149–65.
324 <https://doi.org/10.1038/s42255-021-00347-1>.
- 325 [33] Steenblock C, Richter S, Berger I, Barovic M, Schmid J, Schubert U, et al. Viral infiltration of
326 pancreatic islets in patients with COVID-19. *Nat Commun* 2021;12:3534.
327 <https://doi.org/10.1038/s41467-021-23886-3>.
- 328 [34] Tang X, Uhl S, Zhang T, Xue D, Li B, Vandana JJ, et al. SARS-CoV-2 infection induces beta cell
329 transdifferentiation. *Cell Metab* 2021;33:1577-1591.e7.
330 <https://doi.org/10.1016/j.cmet.2021.05.015>.
- 331 [35] Wu C-T, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, et al. SARS-CoV-2 infects human
332 pancreatic β cells and elicits β cell impairment. *Cell Metab* 2021;33:1565-1576.e5.
333 <https://doi.org/10.1016/j.cmet.2021.05.013>.
- 334

335

336

337

338


339

340

341

342

343 **Supplementary Materials:**



365 **Figure S1. A. Average number of cases per month for every year. B. Total number of monthly cases for every**
366 **year**

367

368

369

370

371

372




Figure S2. In the pandemic group, higher blood glucose levels were noticed in younger patients (27.096 ± 7.322 in children aged < 5 years, 23.832 ± 9.402 in children aged 5–11 years, and 21.928 ± 9.243 in children aged ≥ 11 years, $P = 0.049$). Blood glucose level differences among age categories weren't significant in the control group ($p = 0.076$)